Daiichi Sankyo: Dato-DXd has sufficient potential as an ADC succeeding Enhertu: Daiichi Sankyo

Daiichi Sankyo Korea has dismissed concerns about Dato-DXd (datopotamab deruxtecan), an antibody-drug conjugate (ADC) being developed as a follow-on to Enhertu (trastuzumab deruxtecan).The company said the new predictive biomarker, developed after clinical failures, holds promise as a combination dr